Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
CD55 Double Nickase Plasmid (h): sc-400738-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- CD55 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- CD55 Double Nickase Plasmid (h) and CD55 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting CD55. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: CD55 Antibody (NaM16-4D3): sc-51733
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CD55 Double Nickase Plasmid (h) | sc-400738-NIC | 20 µg | $410.00 | |||
CD55 Double Nickase Plasmid (h2) | sc-400738-NIC-2 | 20 µg | $410.00 |
CD55 (decay-accelerating factor) is a GPI-anchored complement regulatory protein that protects host cells from complement-mediated damage by accelerating the decay of C3/C5 convertases. By limiting formation of downstream effector complexes, CD55 helps shape innate immune surveillance and influences inflammatory signaling at the cell surface and within the microenvironment. Altered CD55 expression or function is associated with dysregulated complement activation and has been studied in contexts including hemolytic disorders, autoimmunity, and tumor immune evasion mechanisms. In vitro, CD55 is commonly used as a marker and functional node for probing complement sensitivity, membrane protein trafficking, and immune-cell interactions.
CD55 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the CD55 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within CD55. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt CD55 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of CD55-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.